Costs of an early intervention versus a conservative strategy in acute coronary syndrome

International Journal of Cardiology

Volumn 127, Issue 2, 2008, Pages 240-246

  Epstein, David M ^a   Sculpher, Mark J ^a   Clayton, Tim C ^b   Henderson, Rob A ^c   Pocock, Stuart J ^b   Buxton, Martin J ^d   Fox, Keith A A ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angina, unstable; Costs and cost analysis; Myocardial revascularization; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; EARLY INTERVENTION; FEMALE; FOLLOW UP; GROUPS BY AGE; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ACUTE CORONARY SYNDROME; CORONARY ANGIOGRAPHY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL REVASCULARIZATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 44849136908     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.008     Document Type: Article

References (23)

1. Fox K.A.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 360 (2002) 743-751
2. Fox K.A.A., Poole-Wilson P.A., Clayton T.C., et al. 5 year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 366 9489 (2005) 914-920
3. Kim J., Henderson R.A., Pocock S.J., Clayton T.C., Sculpher M.J., and Fox K.A.A. Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST elevation myocardial infarction: 1-year results of the RITA-3 trial. J Am Coll Cardiol 45 2 (2005) 221-228
4. Stapel S., Pasanen J., and Reinecke S. Purchasing Power Parities and related economic indicators for EU, Candidate Countries and EFTA Statistics: final results 2002 and preliminary results 2003. Statistics in Focus 53 (2004) 1-7
5. OECD. New GDP Comparisons Based on Purchasing Power Parities for the Year 2002 (2005), OECD, Paris
6. HM Treasury. The green book: appraisal and evaluation in central government (2003), Great Britain HM Treasury, London
7. Sculpher M.J., Smith D.H., Clayton T.C., et al. Coronary angioplasty versus medical therapy for angina. Eur Heart J 23 (2002) 1291-1300
8. Curtis L., and Netten A. Unit costs of health and social care (2004), Personal Social Services Research Unit, Canterbury, Kent
9. Department of Health. NHS reference costs 2003 and National tariff 2004 (2004), Department of Health, London
10. NHS Prescription Pricing Authority. Prescription cost analysis: England 2002 (2003), NHS Prescription Pricing Authority, Newcastle
11. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary 48: British medical association and the Royal pharmaceutical society of Great Britain (2004)
12. ISD Scotland. Costs Book 2004 (2004), ISD Scotland, Edinburgh. http://www.isdscotland.org www.isdscotland.org
13. Etzioni R.D., Feuer E.J., Sullivan S.D., Lin D., Hu C., and Ramsey S.D. On the use of survival analysis techniques to estimate medical care costs. J Health Econ 18 (1999) 365-380
14. Willan A.R., Lin D.Y., and Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med 24 1 (2005) 131-145
15. Barber J.A., and Thompson S. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19 (2000) 3219-3236
16. Efron B., and Tibshirani R. An introduction to the bootstrap (1993), Chapman and Hall, New York
17. Main C., Palmer S., Griffin S., et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 8 40 (2004) 1-153
18. Robinson M., Ginnelly L., Sculpher M.J., et al. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. Health Technol Assess 6 25 (2002) 1-160
19. Hill R., Bagust A., Bakhai A., et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 8 35 (2004) 1-253
20. Hartwell D., Colquitt J., Loveman J., et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol Assess 9 17 (2005) 1-111
21. Mahoney E., Jurkovitz C., Chu H., et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. Jama 288 15 (2002) 1851-1858
22. Janzon M., Levin L., and Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary disease: results from the FRISC II invasive trial. Eur Heart J 23 (2002) 31-40
23. Mehta S., Cannon S., Fox K.A.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta analysis of randomized trials. Jama 293 23 (2005) 2908-2917